3.1801 +0.16 (5.30%)
Pre-Market: 9:23AM EDT
|Bid||3.0400 x 3200|
|Ask||3.2000 x 41800|
|Day's Range||2.7300 - 3.4000|
|52 Week Range||2.1400 - 18.5000|
|Beta (3Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / August 6, 2019 / Endo International Plc (NASDAQ: ENDP ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 6, 2019 at 7:30 ...
- Operating Performance Led by Year-over-Year Double-Digit-Percentage Growth in Revenues of Sterile Injectables Segment and Specialty Products Portfolio of Branded Pharmaceuticals Segment - - Endo Reaffirms ...
In March 2019 , the FDA determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act. As a result, it is unlawful for outsourcing facilities to sell compounded vasopressin products unless they manufacture those products using an FDA-approved vasopressin product, rather than bulk vasopressin, or if vasopressin were to be added to the FDA's drug shortage list. Par Sterile Products, LLC ("Par"), a subsidiary of Endo, is the manufacturer of Vasostrict®, the only vasopressin product approved by the FDA. Following the FDA's decision, Athenex, Inc. and two of its affiliates sued the FDA seeking to overturn the vasopressin decision. Par and another Endo subsidiary intervened as defendants in the action. "At Endo, delivering high quality products and ensuring patient safety are our top priorities and we are very pleased with the district court's decision confirming the FDA's determination that there is no clinical need to bulk compound vasopressin," said Matthew J. Maletta , Executive Vice President and Chief Legal Officer of Endo.
Endo Appoints Domenico Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics
DUBLIN and LUGANO, Switzerland , July 31, 2019 /CNW/ -- Endo International plc (ENDP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, are pleased to announce today that Endo International plc's subsidiary Endo Ventures Limited has entered into definitive agreements with Helsinn to register, commercialize, and distribute Pracinostat on an exclusive basis in Canada upon receipt of the required regulatory approval. Under the terms of the agreement, Paladin Labs Inc., an operating company of Endo, will be responsible for the registration, distribution, sales, marketing, medical affairs, pricing and reimbursement activities in connection with Pracinostat in Canada . Helsinn will be responsible for supplying the drug to Paladin and will retain all international development rights, including clinical development activities.
BRIDGEWATER, N.J. and RALEIGH, N.C., June 18, 2019 -- Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic.
Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal. Endo Pharmaceuticals and Dr. Spitz encourage men to conduct self-penile exams to look for a curvature and feel for a lump this June, which is Men's Health Month.
DUBLIN , May 17, 2019 /CNW/ -- Endo International plc (ENDP) today announced that clinical data from a Phase 3 investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite will be presented by Lawrence Bass , M.D., a board-certified plastic surgeon with a practice in New York City . Dr. Bass will present the Phase 3 data during the Premier Global Hot Topics session, which takes place today from 1:00pm – 6:00pm (Central Time) at the New Orleans Ernest N. Morial Convention Center. The Hot Topics session is considered to be a highlight of The Aesthetic Meeting 2019, the annual meeting of the American Society for Aesthetic Plastic Surgery (The Aesthetic Society).
DUBLIN , May 15, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the RBC Annual Healthcare Conference in New ...
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
DUBLIN , April 10, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2019 financial results on May 9, 2019 and members of its senior management team will host a ...
DUBLIN , April 5, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version ...